Photo / Video
Contact us
Careers
Search
Home
NMS Company
Who We Are
Corporate Governance
Mission
News
Archive
History and Track record
Licensing and Alliances
Information Technology
Working at NMS
Location
Legal info
Oncology
About NMS Oncology
Intellectual Property
Pipeline
Nemorubicin
Danusertib
Milciclib
NMS-1116354
NMS-1286937
Preclinical Programs
Technology Platforms
Payloads and Antibody Drug Conjugates (ADCs)
Capabilities
Lead Optimization and Medicinal Chemistry
Fragment Based Drug Discovery
NMR Screening
Cell Assay Technologies
Cell Bank and Cell Proliferation
Collaborations
Science Corner
Meetings
Publications
Oncology Seminars
M.I.O.
Milano International Oncology
Expertise
Partnerships
Capabilities
Core services
Accelera
NerPharMa / DS
Archive
1
A new agreement has stated the official separation between Nerviano Medical Sciences and Pfizer.
Jun 2, 2010
2
In JCO, Danusertib results of a Phase 1 trial. Phase 2 in patients with lung cancer and other solid tumors ongoing.
Oct 8, 2009
3
FDA approves clinical studies of a novel anti-cancer drug developed by the Italian research
Feb 10, 2009
4
Nerviano Medical Sciences announces a new Collaboration Agreement with Genentech to discover Antibody Drug Conjugates
Oct 21, 2008
5
The DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness".
Jun 27, 2008
6
Three Nerviano Medical Sciences molecules at ASCO
Jun 2, 2008
7
NMS DEVELOPS A NOVEL APPROACH FOR CANCER TREATMENT
May 20, 2008
8
Students face to face with science
May 13, 2008
9
Important new discoveries from NMS on Cdc7 inhibitor, a protein responsible for the proliferation of tumour cells
Apr 15, 2008
10
Nerviano Medical Sciences and Genentech joint strenghts
Jan 9, 2008
Start
Prev
1
2
Next
End
Page 1 of 2
NMS Company
Who We Are
Corporate Governance
Mission
News
Archive
History and Track record
Licensing and Alliances
Information Technology
Working at NMS
Location
Legal info
